Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee

Next Previous
X
Search
Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LEVI 04 (Primary)
  • Indications Musculoskeletal pain
  • Focus Therapeutic Use
  • Sponsors Levicept

    • Most Recent Events

    • 14 Nov 2024 Results presented in the Levicept Media Release.
    • 28 Oct 2024 According to Levicept media release, Professor Philip Conaghan MD, Director NIHR Leeds Biomedical Research Centre, who is the Principal Investigator of this study, will present the data at the ACR Convergence 2024, on Tuesday 19 Nov 2024 at 08:00 EST.
    • 28 Oct 2024 According to Levicept media release, the company will present the results from its Phase II trial of LEVI-04 in an oral presentation at the American College of Rheumatology's annual meeting, ACR Convergence 2024, being held from 14 November to 19 November, 2024 in Washington, DC.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top